

S2) protein was used for antibody responses detection. **Results:** During vaccination program no side effect grade  $\geq 3$  (including allergy, thrombosis, heart dysfunction or laboratory abnormalities) was reported. The commonest complains were fatigue (20%), bony pain (10%) and fever  $<38.5$  oC (10%). Satisfactory antibody responses were observed in 66% and 95% of pts after the 1st and 2nd dose respectively. Importantly, active GvHD and intensive immunosuppression, did not negatively affect the antibody responses. None of the vaccinated pts developed COVID infection **Conclusion:** Our retrospective study although with small number of patients and with short term follow-up, in agreement with others, confirms that the current commercially available vaccines against SARS-CoV-2 are safe and highly effective in producing effective humoral responses in allografted patients. Prospective studies with longer follow-up are needed to elucidate the proper timing and the number of necessary doses for a safe and effective approach in preventing severe COVID-19 infection

<https://doi.org/10.1016/j.htct.2022.09.1216>

## OTHER DISEASES

### OP 10

#### THE MENTAL HEALTH STATUS OF INPATIENTS WITH NEWLY DIAGNOSED HEMATOLOGICAL CANCER DURING THE COVID-19 PANDEMIC

Ferda CAN<sup>1</sup>, Alperen KORKMAZ<sup>2</sup>, Tekin GUNEY<sup>1</sup>, Sema AKINCI<sup>1</sup>

<sup>1</sup> Department of Hematology, Ankara City Hospital, Ankara, Turkey

<sup>2</sup> Department of Psychiatry, Ankara City Hospital, Ankara, Turkey

**Objective:** There is limited data in the literature on the mental health of newly diagnosed hematological cancer (HC) patients in COVID-19 pandemic. This study evaluates the mental health statuses of HC inpatients diagnosed during the COVID-19 pandemic in comparison to the statuses of patients diagnosed with HC before the pandemic. **Methodology:** A cross-sectional survey collected the mental health measurements of 77 inpatients with HC between March and May 2021. The levels of depression, generalized anxiety, distress, sleep disorder, health anxiety, trait anxiety, coronaphobia, and resilience in HC patients newly diagnosed during the pandemic (NDHC) (n=38) and HC patients diagnosed before the pandemic (BPHC) (n=39) were compared. The relationships between predictive factors and cancer patients' mental health statuses were evaluated. **Results:** Depression (63.2% vs. 35.9%, p=0.017) and sleep disorder (67.8% vs. 38.5, p=0.016) were significantly higher, while generalized anxiety (57.9% vs. 38.5%, p=0.088) and distress (52.6% vs. 33.3%, p=0.087) were higher in NDHC. Health anxiety was more common in BPHC (53.8% vs. 31.6%, p=0.048). Among NDHC, women had more anxiety

symptoms than men (76.5% vs. 42.9%, p=0.037). Diagnosing newly increased the risk of severity of depression and sleep disorders, but decreased the risk of health anxiety. **Conclusion:** Our data indicate that patients with HC are vulnerable to mental health problems in the COVID-19 pandemic. This vulnerability is higher in newly diagnosed HC patients than in patients diagnosed before the pandemic. These findings may help develop interventions that reduce the vulnerability to adverse psychological effects by identifying risk factors for HC patients under pandemic conditions.

<https://doi.org/10.1016/j.htct.2022.09.1217>

### OP 11

#### CORONAVIRUS ANXIETY LEVEL AND COVID 19 VACCINE ATTITUDE AMONG HEMATOLOGICAL MALIGNANCY PATIENTS

Zeynep Tuğba GÜVEN<sup>1</sup>, Muzaffer KEKLIK<sup>2</sup>, Ali ÜNAL<sup>2</sup>

<sup>1</sup> Kayseri City Hospital, Department of Hematology, Kayseri, Turkey

<sup>2</sup> Erciyes University, School of Medicine, Department of Hematology, Kayseri, Turkey

**Objective:** The COVID-19 vaccine is the most essential tool for altering the pandemic's trajectory. The pandemic's control is complicated by society's unwillingness to vaccination. The aim of this study was to evaluate the attitudes of patients with hematological malignancies towards vaccination and to determine the relationships between vaccination hesitancy and patient characteristics. The secondary aim was to identify the pandemic-related anxiety level of this patient group and to investigate whether anxiety influences vaccination propensity. **Methodology:** This cross-sectional study was conducted with hematological malignancy patients at Hematology Clinic of the Erciyes University Hospital from Kayseri, Turkey, from 1 May 2021 to 1 December 2021. Patients who <sup>(1)</sup> were 18 years old or older, <sup>(2)</sup> voluntarily agreed to take part survey, and <sup>(3)</sup> could understand and perform the questionnaire met the inclusion criteria. 165 patients with hematological malignancies were included. The questionnaire consisted of three parts. The patients' sociodemographic characteristics, such as age, gender, diagnosis, disease and HSCT status, education level, marital status, location of residence were all asked about in the first section of the study. COVID-19 anxiety situation was evaluated with the Coronavirus Anxiety Scale (CAS). COVID-19 vaccine attitude was evaluated with the Vaccine Attitudes Review (VAX) Scale. **Results:** The median age was 48 (18 - 86) years, 61 (37%) of whom were female. Most of the participants (37%) had been diagnosed with acute myeloid leukemia and were undergoing chemotherapy. In addition, 21% of patients reported having comorbidities. At the time of the survey, 70% of patients had not been infected with COVID-19, whereas 44% had been vaccinated. The mean CAS score was 2.42 (0 - 17). There were 22 (13%) participants with a mean CAS score of  $\geq 9$ . Half of the participants had a CAS

score of 0. The CAS score was higher in females ( $p=0.023$ ). Similarly, it was significantly higher in patients who were not in remission for hematological malignancy and who received active chemotherapy ( $p=0.010$ ). The mean VAX score was  $49.07 \pm 8.76$  (27-72). Most of the participants (64%) had a neutral attitude towards COVID-19 vaccination. In a survey of 165 patients, 55% said that they were skeptical about vaccination safety, and 58% said that they were concerned about unintended side effects. In addition, 90% expressed moderate concerns about commercial profiteering. Natural immunity was preferred by 30% of the participants. There was no statistically significant correlation between CAS scores and Vaccine Attitudes Review (VAX) Scale. **Conclusion:** This study draws attention to the level of anxiety in patients with hematological malignancies of the COVID-19 pandemic. Negative attitudes towards the COVID-19 vaccine are worrisome for at-risk patient groups. We think that patients with hematological malignancies should be informed to eliminate their hesitations about COVID-19 vaccines.

<https://doi.org/10.1016/j.htct.2022.09.1218>

#### OP 12

##### TREATMENT OF A PATIENT DIAGNOSED WITH ERDHEIM CHESTER'S DISEASE IN COOPERATION WITH PLASTIC SURGERY AND HEMATOLOGY

Simge ERDEM<sup>1</sup>, Dilek Özden ÖZLÜK<sup>1</sup>, Erol KOZANOĞLU<sup>2</sup>, Sevgi KALAYOĞLU BEŞİŞİK<sup>1</sup>

<sup>1</sup> Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology

<sup>2</sup> Istanbul University Istanbul Faculty of Medicine, Department of Plastic and Reconstructive Surgery

**Objective:** Erdheim Chester disease (ECD) is a rare non-Langerhans histiocytic multisystem disorder. ECD is most commonly manifested as multifocal sclerotic long bone lesions. Orbital and intraocular manifestations are rare. We report an unusual bilateral orbital presentation as xanthomatous infiltration of ECD. **Case report:** A 56-year-old male was admitted due to papular lesions on both eyelids. Eyelid tissue histology showed histiocytic infiltration consistent with ECD. BRAF V600E mutation (-). In the first year, PET-CT showed new lesions on the lymph node, eyelids, knees and elbows. Laboratory investigation was within normal apart of mild increased CRP. The disorder was unresponsive to pegylated interferon alfa. With cladribine of 3 courses and surgical intervention he achieved a nearly normal facial appearance. **Conclusion:** Uncontrolled cell survival, differentiation, and proliferation of histiocytes in ECD result in soft tissue thickening and progressed to chronic fibrotic disease which may be unresponsive to medical treatments and requires surgical interventions.

<https://doi.org/10.1016/j.htct.2022.09.1219>

#### OP 13

##### A RARE PRESENTATION OF SYSTEMIC AL AMYLOIDOSIS; PULMONARY AL AMYLOIDOSIS

Simge ERDEM<sup>1</sup>, Nigar TAGHIYEVA<sup>1</sup>, Kaan AKIN<sup>2</sup>, Hilal KONYAOĞLU<sup>2</sup>, Sevgi KALAYOĞLU BEŞİŞİK<sup>1</sup>

<sup>1</sup> Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine, Division of Hematology

<sup>2</sup> Istanbul University Istanbul Faculty of Medicine, Department of Internal Medicine

**Objective:** Involvement of the lung is common in systemic AL amyloidosis in post-mortem series. However, the diagnosis is challenging. Histology is the gold standard but may result in bleeding. Consequently, diagnosis during life is rare. **Case report:** A 58-year-old female was admitted with chest pain, weight loss and cough. Thorax CT showed diffuse ground glass opacities, increased nodular density, and conglomerated mediastinal lymph nodes. Lung biopsy revealed Congo red (+) and anti-amyloid A (-). Bone marrow showed clonal plasma cell increase as 15% of kappa type. No other organ involvement or lytic lesions on PET-CT were documented. Cardiac involvement was detected. Daratumumab-bortezomib-based treatment with doxycycline was started. **Conclusion:** Clinical symptoms and laboratory testing cannot specially confirm the diagnosis of pulmonary amyloidosis. The usual presentation is diffuse-alveolar septal involvement. Diffuse parenchymal involvement is one of the least common forms of respiratory amyloidosis. It should be considered in the differential diagnosis in elderly patients.

<https://doi.org/10.1016/j.htct.2022.09.1220>

#### PP14

##### REAL-LIFE STUDY OF BIO-CLINICAL FOLLOW-UP AFTER BNT162b2 mRNA COVID-19 (BNTCV) VACCINATION IN 235 PATIENTS (PTS) INCLUDING 225 WITH HEMATOLOGICAL MALIGNANCIES (HM).

Jean-François Rossi<sup>1,2</sup>, Emmanuel Bonnet<sup>3</sup>, Marion Velensek<sup>1</sup>, Emma Wisniewski<sup>1</sup>, Sophie Heraud<sup>1</sup>, Rania Boustany<sup>1</sup>, Céleste David<sup>1</sup>, Jérôme Dinot<sup>4</sup>, Roland Sicard<sup>1</sup>, Jean-Pierre Daures<sup>3</sup>, Marion Bonifacy<sup>5</sup>, Lysiane Mousset<sup>5</sup>, Christel Castelli<sup>3</sup>, Emmanuel Goffart<sup>5</sup>

<sup>1</sup> Institut du Cancer Avignon-Provence, Sainte Catherine, Avignon, France

<sup>2</sup> Faculté de Médecine Montpellier, Université de Montpellier, Montpellier, France

<sup>3</sup> Recherche Clinique Clinique Beau Soleil – Nouvelles Technologies, Montpellier, France

<sup>4</sup> La Valériane Inc., 130 Rue de la Jasse de Maurin, 34070 Montpellier, France